Table 7 Study cohort characteristics stratified by COPD re‑admission with a 2-year follow-up

Age^a

49

67(63,73)

75

70(63,73)

0.31

Female gender^b

43

87.8%

61

81.3%

0.46

BMI^a

49

20.8(17.7,22.8)

75

21.2(18.4,22.8)

0.68

Smoking Index ^a

49

600(375,950)

75

600(0,1350)

0.95

Duration of COPD^a

49

10(6,25)

75

13(6,20)

0.93

Comorbidities^b

23

46.9%

42

56.0%

0.36

Diabetes mellitus^b

4

8.2%

10

13.3%

0.56

Coronary disease^b

2

4.1%

6

8.0%

0.48

Stroke^b

1

2.0%

2

2.7%

1.00

Hypertension^b

20

40.8%

38

50.7%

0.36

Home oxygen therapy^b

25

51.0%

21

28.0%

0.01

Regular medication^b

32

65.3%

37

49.3%

0.10

Oral glucocorticoid therapy^b

1

2.0%

4

5.3%

0.65

Theophylline therapy^b

2

4.1%

0

0%

0.15

Expectorants therapy^b

14

28.6%

20

26.7%

0.84

Inhaled COPD therapy^b

-

-

-

-

0.04

No inhaled treatment^b

3

6.1%

17

22.7%

LAMA^b

4

8.2%

5

6.7%

ICS + LABA^b

5

10.2%

15

20.0%

LABA + LAMA^b

7

14.3%

9

12.0%

ICS + LABA + LAMA^b

30

61.2%

29

38.7%

SGRQ score^a

49

46.2(36.9,73.1)

75

34.9(25.2,60.0)

0.005

mMRC score^a

49

2(1,3)

75

1(1,3)

0.005

Exercise capacity score^a

49

2(1,2)

75

1(1,2)

0.008

CAT score^a

49

24(19,29)

75

20(13,27)

0.01

COPD-related exacerbation within the previous year^a

49

1(0,2)

75

0(0,1)

0.0002